Olysio’s Stronger-Than-Expected Sales Drive Strong Quarter For J&J
This article was originally published in The Pink Sheet Daily
Products launched since 2009 have yielded the highest pharmaceutical sales growth among the 10 biggest biopharma companies, more than offsetting a substantial patent cliff. Zytiga and Olysio already have passed the $1 billion sales threshold this year, with Xarelto on pace to do so.
You may also be interested in...
Emerging Markets Earnings Roundup: Johnson & Johnson (Part 1)
Second quarter earnings from Johnson & Johnson shed light on the view on biosimilar launches of Remicade and how the company hopes to streamline its varied arms abroad.
Medivation/Astellas Will Be Ready For Xtandi To Enter Pre-Chemo Prostate Cancer Setting
The oncology drug has been submitted for approval in the larger chemotherapy-naïve patient population and Medivation intends to increase its sales force to support the launch.
FDA Approves Zytiga In Earlier Prostate Cancer Setting
FDA approval of Zytiga in the pre-chemo setting gives the androgen blocker a second prostate cancer indication and another revenue stream – but a short remaining patent life and a significant competitive threat may mitigate the achievement.